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Purpose: Wild-type myocilin is known to be secreted extracellularly, but a significant amount of the protein is also present
in the endoplasmic reticulum (ER). The present study was undertaken to address whether intracellular myocilin is a true
ER resident protein.
Methods: Human wild-type myocilin was adenovirally expressed in human trabecular meshwork cells, and general
characteristics of both intracellular and extracellular myocilins including molecular weight, pI, glycosylation state, and
cleavage site of the signal peptide were examined by biochemical analyses. Topology and decay kinetics of myocilin were
also examined by protease protection assay and pulse chase analysis, respectively. The expression pattern and cytopathic
effect of myocilin were analyzed in individual cells by immunocytochemistry.
Results: Intracellular myocilin were very similar to secreted myocilin in characteristics such as molecular weight, pI,
glycosylation state, and cleavage site of the signal peptide. The intracellular protein was found to be present in the lumen
of the ER where it appeared to be retained without further export to the Golgi apparatus. The kinetics of myocilin turnover
clearly showed that it was intrinsically a very stable but incompletely secreted protein. The expression of myocilin was
confined to a subset of cells and accompanied by the upregulation of a 78 kDa glucose-regulated protein, suggesting that
it was not properly folded or processed in the ER.
Conclusions: Based on these findings and the fact that myocilin has no known ER retention signals, the ER localization
of wild-type myocilin is likely a consequence of its incomplete secretion due to its misfolding.
Primary open-angle glaucoma (POAG) characterized by
the gradual death of retinal ganglion cells is the most common
form of glaucoma that develops in up to 2% of people older
than 40 years of age [1-3]. The major risk factor for POAG is
an elevated intraocular pressure (IOP), which is consequent
to  the  decreased  aqueous  outflow  through  the  trabecular
meshwork (TM), a reticulated tissue at the junction of the
cornea and iris through which approximately 90% of aqueous
humor (AH) exits [1,2].
MYOC, encoding a glycoprotein termed myocilin, was
the first gene linked to POAG [4]. Myocilin is an acidic protein
with a molecular weight of 55 kDa and comprises two major
domains, an NH2-terminal coiled coil domain with a leucine
zipper-like  motif  and  a  COOH-terminal  olfactomedin-like
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domain. The NH2-terminal domain has 77.6% homology with
the  myosin  heavy  chain  of  Dictyostelium  discoideum  and
shares 25% identity with the cardiac beta myosin heavy chain
[5,6]. These analogies have led to the protein name myocilin
[6].
Currently,  up  to  70  different  disease-causing  MYOC
mutations have been described in patients with autosomal
dominant juvenile open-angle glaucoma and some forms of
adult-onset POAG [7-9]. Fingert et al. [10] termed POAG
caused by MYOC mutations “myocilin glaucoma”. It has been
estimated that myocilin glaucoma accounts for about 3%−4%
of all cases of POAG [7-9].
Although little is known about the functions of myocilin,
it has been suggested that myocilin mutations in humans likely
act through a gain of function [11-13]. Biochemical and cell
biological  studies  gave  supportive  results  that  myocilin
mutants  are  not  secreted  but  retained  in  the  endoplasmic
reticulum (ER) [14-19]. It has been reported that retention of
myocilin mutants in the ER initially leads to ER stress and
eventually to the death of human trabecular meshwork (HTM)
cells [16-18]. Pathologically, cell death is a critical component
of gain of function because it inevitably leads to diminution
in the cell number of the TM, a hallmark of POAG [20,21].
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545However, it is uncertain whether such a scenario also occurs
in wild-type myocilin.
There is no doubt that wild-type myocilin is normally
secreted because numerous studies have reported its detection
in culture media of various cell lines in vitro [14-19,22-27]
and in the AH of several species including humans in vivo
[15,26,28,29]. It should be noted, however, that a significant
amount of wild-type myocilin is also present intracellularly
[14,15,19,22-27],  especially  in  the  ER  [16-18].  Although
examples are being found of proteins that are resident and
function  in  more  than  one  cellular  compartment,  an  ER
location is unusual for secretory proteins. Generally, proteins
retained  in  the  ER  are  categorized  into  two  types,  the
misfolded or incompletely assembled proteins and the ER
resident proteins. Presently, there is no evidence to suggest
that myocilin is an actual ER resident protein.
In this study, we characterized both the intracellular and
extracellular myocilins in an effort to better understand the
characteristics  of  myocilin  in  the  ER.  Herein,  we  present
evidence that does not support the hypothesis that intracellular
myocilin is a true ER resident protein.
METHODS
Cell culture: HTM cells derived from the normal eyes of a 27-
year-old female donor were a generous gift from Paul L.
Kaufman (University of Wisconsin, Madison, WI). Human
embryonic kidney 293A cells were purchased from Qbiogene
(Carlsbad,  CA).  These  cells  were  cultured  in  Dulbecco’s
modified  Eagle’s  medium  (DMEM;  Life  Technologies,
Rockville, MD) supplemented with 10% fetal bovine serum
(FBS;  Life  Technologies)  and  antibiotics  (100  units/ml
penicillin, 100 μg/ml streptomycin, and 20 μg/ml gentamicin)
at 37 °C in a humidified chamber with 5% CO2.
Viral  constructs:  Replication-deficient  recombinant
adenoviruses expressing human wild-type myocilin tagged
with  the  FLAG  epitope  (Asp-Tyr-Lys-Asp-Asp-Asp-Asp-
Lys) at its COOH-terminus (Ad-myocilin-FLAG) or at its
NH2-terminus (Ad-FLAG-myocilin) were generated using the
AdEasyTM system (Qbiogene) according to the manufacturer’s
protocol. To construct a vector encoding myocilin with a
FLAG tag at its COOH-terminus, the open reading frame of
myocilin  without  the  stop  codon  was  excised  from  the
pΔACMV-wild-type  myocilin-GFP  vector  that  encodes  a
fusion protein joining human myocilin to the NH2-terminus
of the green fluorescence protein (GFP) [16]. The excised
myocilin cDNA was then inserted into the BamH 1 and Age
1  sites  of  the  pShuttle-CMV  vector  (Qbiogene)  that  was
previously modified by inserting an adaptor containing an
Age 1 site and the sequences for the FLAG epitope. The
adaptor was generated by annealing primers 5′-TCG AGA
CCG GTC GAT TAC AAG GAT GAC GAC GAT AAG
TAG-3′ and 5′-CTA GCT ACT TAT CGT CGT CAT CCT
TGT AAT CGA CCG GTC-3′. To construct a vector encoding
myocilin with a FLAG tag at its NH2-terminus, cDNA for
myocilin was amplified by polymerase chain reaction (PCR)
using  the  pΔACMV-wild-type  myocilin-GFP  vector  as  a
template with primers 5′-NNN GGA TCC AGG AAG CCT
CAC CAA GCC-3′ and 5′-NNN AAG CTT CAC ATC TTG
GAG AGC TT-3′ and then cloned into the BamH 1 and Hind
III  sites  of  the  pShuttle-CMV  vector  that  was  previously
adapted by inserting the sequences for the FLAG epitope. The
region encoding the FLAG epitope was amplified by PCR
from the pCMV-Tag 2B vector (Stratagene, La Jolla, CA)
using primers 5′-NNN AGA TCT GCC ACC ATG GAT TAC
AAG-3′ and 5′-NNN AAG CTT GAT ATC GAA TTC CTG
CAG-3′. The resulting shuttle vectors encoding the FLAG-
tagged  myocilins  were  linearized  with  Pme  1  and  co-
transformed into BJ5183 along with pAdEasy-1, a plasmid
containing the adenovirus serotype 5 genome with deletions
in  the  E1  and  E3  regions.  The  recombinant  adenoviral
constructs were selected with kanamycin, cleaved with Pac 1,
and then transfected into 293A cells to produce viral particles.
Viral titers were determined by limiting dilution on 293A
cells,  and  the  absence  of E1a  in  the  viral  constructs  was
confirmed by PCR. Other adenoviruses expressing GFP alone
(Ad-GFP), myocilin with its COOH-terminus tagged with
GFP (Ad-myocilin-GFP), a myocilin mutant with an Y437H
mutation (Ad-Y437H myocilin-GFP), and stromelysin (Ad-
stromelysin-GFP) have been previously described [16,17].
Unless specified otherwise, viral transduction was performed
for 2 h at a multiplicity of infection (MOI) of 10 plaque
forming units (pfu) per cell, and the transduced cells were
further cultured for 48 h.
Western  blot  analysis:  Protein  samples  were  mixed  with
Laemmli sample buffer, boiled for 5 min, and subjected to
sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS–PAGE). The resolved proteins were transferred to a
nitrocellulose membrane and blocked with 5% skim milk in
Tris  buffered  saline  (TBS)  containing  0.05%  Tween-20
(TTBS) overnight. The membrane was incubated for 2 h with
anti-myocilin antibody diluted 1,000 fold, monoclonal anti-
FLAG antibody (Sigma, St Louis, MO) diluted 2,000 fold, or
monoclonal  anti-calnexin  antibody  (BD  Transduction
Laboratories, Lexington, KY) diluted 500 fold in TTBS. The
anti-myocilin  antibody  was  raised  in  rabbits  against  the
peptide sequence Arg-Leu-Arg-Gln-Glu-Asn-Glu-Asn-Leu-
Ala-Arg-Arg that corresponds to positions 158–169 of human
myocilin.  After  washing  three  times  with  TTBS,  the
membrane was reacted for 2 h with peroxidase-conjugated
anti-mouse  or  anti-rabbit  antibodies  (Amersham,
Buckinghamshire,  UK)  diluted  2,000  fold  in  TTBS.  The
membrane was washed three times and then probed with the
chemiluminescence kit (Amersham) using the manufacturer’s
protocol.
Enzymatic deglycosylation: For endoglycosidase H (Endo H)
and  N-glycosidase  F  (PNGase  F;  New  England  Biolabs,
Ipswich, MA) digestions, samples were denatured with 0.5%
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Endo H digestion, the denatured samples were mixed with
50 mM sodium citrate (pH 5.5) plus 500 units of the enzyme.
For the PNGase F treatment, the samples were suspended in
50 mM sodium phosphate buffer (pH 7.5) containing 1%
NP-40  as  well  as  500  units  of  the  enzyme.  For
endoglycosidase  D  (Endo  D;  Seikagaku,  Tokyo,  Japan)
digestion, cell lysates prepared in lysis buffer composed of
50 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1% Triton
X-100, and 1X protease inhibitor (Roche, Indianapolis, IN)
were mixed with citrate-phosphate buffer (pH 6.5) to a final
concentration of 150 mM and 10 milliunits of the enzyme was
added. All deglycosylation reactions were done at 37 °C for
1 h.
Amino acid sequencing: Confluent HTM cells in a 100 mm
culture  dish  were  transduced  with  Ad-myocilin-FLAG,
washed thoroughly with serum-free DMEM, and then further
cultured with the serum-free media. Forty-eight hours after
transduction, the media (5 ml) was collected, spun at 14,000x
g  for  20  min  to  eliminate  insoluble  materials,  and  then
concentrated  25  fold  (final  volume  of  200  μl)  using  a
centrifugal  filter  device  (Centricon  YM-30;  Millipore,
Corporation, Bedford, MA). The cells were lysed with 1 ml
lysis buffer, spun briefly, and then 200 μl of 50% anti-FLAG
M2 affinity gel slurry (Sigma) was added. The mixtures were
spun again, and the pellet was washed twice with TBS. Protein
elution was performed by a competition with 200 μl of 450 ng/
μl 3X FLAG (Sigma). The purified proteins and concentrated
media  were  subjected  to  SDS–PAGE,  and  the  resolved
proteins  were  transferred  to  a  polyvinylidene  fluoride
membrane and stained with a Coomassie brilliant blue R250.
For  NH2-terminal  amino  acid  sequencing  via  the  Edman
degradation  method,  the  Coomassie  stained  proteins  were
excised  from  the  membrane  and  installed  into  the  blot
cartridge of a Perkin-Elmer protein sequencer (Molde 491A;
Perkin-Elmer, Foster City, CA).
Two-dimensional gel electrophoresis: HTM cells transduced
with Ad-myocilin-FLAG in a 100 mm dish were cultured with
serum-free media. After 48 h, the media (5 ml) was collected
and added with 50 μl of Triton X-100 and 100 μl of 50X
protease inhibitor while cells were lysed with 5 ml of the
medium  containing  1%  Triton  X-100  plus  1X  protease
inhibitor. Both cell lysates and media were then precipitated
with the 2D Clean-Up Kit (Amersham) and solubilized in 5%
IPG (immobilized pH gradient) buffer containing 8 M urea,
2%  3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate (CHAPS), and 60 mM DTT. The dissolved
proteins were applied on 17 cm IPG (pH 4–7) linear strips
(Amersham)  and  allowed  to  be  rehydrated  at  ambient
temperature overnight. Isoelectric focusing started at 300 V
for 1 hour, continued with a gradient at 1,000 V for 1 h and
8,000 V for 6 h, and finished at a total of 49,300 Vh. The
focused  strips  were  immersed  in  succession  with  the
equilibration buffer (50 mM Tris, pH 8.8; 6 M urea; 2% SDS;
130  mM  DTT;  20%  glycerol)  and  the  same  buffer
supplemented with 135 mM iodoacetamide instead of DTT
for 15 min each. The strips were washed with running buffer
(25 mM Tris, 192 mM glycine, 0.1% SDS, pH 8.3), secured
on top of a 13% acrylamide gel, and then electrophoresed at
100 V until the bromophenol blue reached the bottom of the
gel. The resolved gels were then processed for western blot
analysis, and the proteins were probed with monoclonal anti-
FLAG antibody.
Metabolic labeling and immunoprecipitation: HTM cells in a
24 well culture plate were transduced with Ad-myocilin-GFP
or  Ad-stromelysin-GFP.  Twenty-four  hours  post-
transduction, the cells were starved for 90 min in methionine-
free  DMEM,  pulse-labeled  for  30  min  with  50  μCi
[35S]methionine  (Amersham),  and  chased  with  DMEM
containing 10 mM methionine in the presence or absence of
acetyl-leucyl-leucyl-norleucinal (ALLN, 10 μg/ml; Sigma).
After  the  appropriate  duration  of  chase,  the  media  was
harvested,  and  the  cells  were  lysed  with  0.3  ml  of
immunoprecipitation buffer (50 mM Tris, pH 7.5; 150 mM
NaCl;  1%  NP-40;  10%  glycerol;  1X  protease  inhibitor
mixture). The media and cell lysates were spun at 14,000x g
for 20 min, and 100 μl of the supernatants were mixed with
2 μg of monoclonal anti-GFP antibody (Sigma) and 20 μl of
50% protein A-agarose slurry (Santa Cruz Biotechnologies,
Santa Cruz, CA). The mixtures were briefly centrifuged, and
the pellet was washed twice with immunoprecipitation buffer
followed by washing once with phosphate buffered saline
(PBS). The pellets were suspended with 20 μl of 1X Laemmli
sample buffer, boiled, and resolved on a 10% polyacrylamide
gel. The gel was dried, and autoradiography was performed.
Protease  protection  assay:  Sealed  microsomal  membrane
vesicles were prepared from ~107 transduced HTM cells using
an Endoplasmic Reticulum Isolation Kit (Sigma). The crude
microsomal  fraction  was  pelleted  by  centrifugation  at
100,000x g for 60 min and suspended in 0.2 ml of 10 mM 4-
(2-hydroxyethyl)piperazine-1-ethanesulfonic  acid  (HEPES;
pH 7.8) containing 250 mM sucrose, 25 mM KCl, 1 mM
ethylene  glycol-bis(2-aminoethylether)-N,N,N',N'-
tetraacetic acid (EGTA), and 1X protease inhibitor. Aliquots
of the membrane suspension (15 μl) equivalent to ~20 μg of
protein were incubated in a total volume of 18 μl with varying
amounts of freshly prepared proteinase K (final concentration
~0.0-0.1 mg/ml) in the presence and absence of 1% (v/v)
Triton X-100 for 30 min on ice. The reactions were stopped
by the addition of 2 μl of 200 mM phenylmethylsulfonyl
fluoride and 7 μl of 4X Laemmli sample buffer after which
the samples were boiled and immediately subjected to western
blot analysis.
Immunocytochemistry:  Transduced  HTM  cells  in  4  well
chamber slides were washed once with PBS, fixed for 20 min
with 4% paraformaldehyde, and permeabilized for 5 min with
0.5% Triton X-100. The cells were blocked with 2% bovine
Molecular Vision 2009; 15:545-556 <http://www.molvis.org/molvis/v15/a55> © 2009 Molecular Vision
547serum albumin (BSA) for 1 h and incubated for 2 h with
fluorescein  isothiocyanate  (FITC)-conjugated  or  non-
conjugated monoclonal anti-FLAG antibody (Sigma) diluted
200 fold or monoclonal anti-78 kDa glucose-regulated protein
(GRP78) antibody (BD Transduction Laboratories) diluted
100  fold.  The  cells  were  washed,  reacted  for  2  h  with
tetramethylrhodamine  isothiocyanate  (TRITC)-conjugated
anti-mouse  immunoglobulin  antibody  (Zymed,  South  San
Francisco,  CA)  diluted  50  fold.  After  the  nuclei  were
counterstained  for  20  min  with  4’,  6’-diamidino-2-
phenylindole  (DAPI),  the  cells  were  viewed  under  a
fluorescence microscope with the appropriate filter sets and a
400X objective.
Labeling  of  adenovirus:  Prior  to  fluorescence  labeling,
recombinant  adenovirus  was  purified  by  double  cesium
chloride  gradient  centrifugation  according  to  the
recommendations of the AdEasyTM system. The purified virus
Figure  1.  Electrophoretic  mobility  and  glycosylated  status  of
intracellular and extracellular wild-type myocilins. HTM cells were
plated into a 24 well plate, grown to 70% confluence, and transduced
for 2 h with Ad-myocilin-FLAG at an MOI of 10 pfu. After 48 h, the
cells and culture media were harvested and the myocilin in the
samples  were  analyzed  by  western  blot  using  polyclonal  anti-
myocilin  antibody.  A:  Cells  and  culture  media  were  harvested
together  (lane  1),  or  cells  and  culture  media  were  separately
harvested (lane 2 and 3), or cells were replenished after culture with
fresh culture media and then cells and culture media were harvested
together (lane 4), or cells were cultured with serum-free culture
media and then the conditioned media was harvested (lane 5). Cells
were harvested with 0.4 ml of 1X Laemmli sample buffer whereas
culture media (0.3 ml) was harvested with 0.1 ml of 4X Laemmli
sample buffer. B: Myocilin in cells (lane 2 and 3) or media (lane 5
and  6)  was  treated  with  Endo  H  (lane  2  and  5)  or  PNGase  F
glycosidase (lane 3 and 6) as described in Methods. Undigested
myocilins in cells (lane 1) and culture media (lane 4) served as
controls. C: Myocilin in cells was either treated (lane 1) or not treated
(lane 2) with Endo D glycosidase.
was then labeled with a chloromethylbenzamido derivative of
Dil (CM-Dil; Molecular Probes, Eugene, OR) following the
manufacturer’s guidelines with slight modifications. Briefly,
20 μl of the viral stock (~1011 pfu/ml) was diluted with an
equal volume of Hank’s balanced salt solution (HBSS) and
mixed with 40 μl of 100 mM CM-Dil prepared in HBSS. The
viral mixture was incubated for 5 min at 37 °C and for an
additional 15 min at 4 °C. Gel filtration chromatography with
a G-50 Sephadex column (Roche) was used to isolate the
fluorescently labeled viral particles.
RESULTS
Intracellular myocilin is identical with its secreted form: As
a  first  step  toward  elucidating  the  mechanism  by  which
myocilin is localized to the ER, we attempted to find evidence
for  the  presence  of  myocilin  isoforms  because  multi-
compartmentalized proteins are generally present as isoforms
with different topogenic sequences that are specific for each
compartment  [30].  We  constructed  a  human  wild-type
myocilin carrying the FLAG epitope at its COOH-terminus
(myocilin-FLAG), expressed the construct in the HTM cells
by using adenoviral vector, and then examined the previously
characterized myocilin expression in the ocular cells that are
relevant to glaucoma research.
It has been reported that in the standard conditions of
SDS–PAGE,  the  mobility  of  secreted  myocilin  is  slightly
increased compared to intracellular myocilin, although both
myocilins are resolved as a doublet at a molecular weight of
approximately 55−57 kDa (compare lane 2 with lane 3 in
Figure 1A) [15,24]. The different mobility of the intracellular
myocilin  compared  to  the  extracellular  myocilin  implies
different  molecular  weights,  which  can  be  accepted  as
Figure  2.  Characterization  of  the  signal  sequence  cleavage  of
myocilin. A: HTM cells were transduced with Ad-myocilin-FLAG
and myocilin in cells (lane 1), and culture media (lane 2) were
separated by SDS–PAGE, transferred to the membrane, and loaded
into a protein sequencer. All myocilin bands yielded the same results
with respect to their NH2-terminal amino acid sequences. B: HTM
cells were transduced with Ad-FLAG-myocilin and myocilin in the
cells (lane 2), and culture media (lane 3) was detected by western
blot analysis using anti-myocilin antibody (upper panel) or anti-
FLAG antibody (lower panel). Myocilin-FLAG (Figure 1A, lane 2)
was included as a control (lane 1).
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548evidence for the presence of myocilin isoforms. However, the
mobility of the intracellular myocilin also increased when cell
lysates were added with culture media containing FBS (lane
4 in Figure 1A). By contrast, the mobility of the secreted
myocilin decreased when cells were cultured without FBS
(lane 5 in Figure 1A) or only increased mobility was observed
when the cell lysate and medium were combined (lane 1 in
Figure  1A).  Therefore,  the  fast  mobility  of  the  secreted
myocilin must have been an artifact.
It has also been reported that the upper bands of the
myocilin doublet correspond to the glycosylated forms of the
lower bands [14,19,22,25], but a recent study showed that
myocilin is not glycosylated [27]. To clarify this discrepancy,
we reexamined the effect of deglycosylation on the doublet.
The treatment of Endo H resulted in a shift of the upper band
into the lower band in the intracellular myocilin but not in the
extracellular myocilin (lane 2 and 5 in Figure 1B) while the
treatment  with  PNGase  F  induced  a  shift  in  both  the
intracellular  and  extracellular  myocilins  (lane  3  and  6  in
Figure 1B). Endo H removes N-glycans of a high mannose
type  whereas  PNGase  F  completely  digests  all  N-linked
oligosaccharides.  Thus,  these  results  support  the  earlier
finding that myocilin can be glycosylated in the ER and then
further processed in the Golgi apparatus. We also examined
the effect of Endo D on the doublet to determine whether
intracellular myocilin is statically retained in the ER without
recycling  or  retrieved  from  the  cis-Golgi.  Endo  D  is  a
specialized carbohydrate cleaving enzyme that distinguishes
glycoproteins that are never exported out of the ER from those
entering the cis-Golgi [31]. There was no shift in the upper
band of the intracellular myocilin after treatment with Endo
D  (Figure  1C),  revealing  that  at  least  the  glycosylated
myocilin is localized to the ER by a retention mechanism.
We determined the NH2-terminal amino acid sequence of
myocilin and obtained the following sequence: Arg-Thr-Ala-
Gln-Leu,  which  matches  the  residues  33–37  of  myocilin
where the predicted cleavage site of the ER targeting signal
sequence of myocilin starts [32]. We found no differences in
the  sequences  between  intracellular  and  extracellular
myocilin and between the upper and low bands of both of the
myocilins (Figure 2A), demonstrating that the signal sequence
is cleaved off all forms of myocilin. Consistent with these
results, myocilin with its NH2-terminus tagged with FLAG
was detected by anti-myocilin antibody but not by anti-FLAG
Figure 3. Two dimensional analysis of
myocilin expression. Myocilin isoforms
in cell lysate (upper panel) and culture
medium (lower panel) from HTM cells
transduced  with  Ad-myocilin-FLAG
were first separated by their isoelectric
points and then resolved according to
their  molecular  weights.  Myocilin
detection was performed by western blot
analysis  using  anti-FLAG  antibody.
This  experiment  was  performed  two
times,  and  representative  gels  are
shown.
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549antibody in both the cell lysate and culture medium. However,
myocilin-FLAG was clearly detected by anti-FLAG antibody
(Figure 2B).
Previously,  two  dimensional  (2D)  PAGE  analysis  of
myocilin expression showed that multiple isoforms could be
detected in cell lysates of human optic nerve head cells or in
the media of human lamina cells as well as in cell lysates and
media  of  dexamethasone-treated  HTM  cells  [22,23,33].
Because  2D-PAGE  is  the  only  method  used  to  describe
myocilin isoforms in the literature, we also used it to identify
myocilin  isoforms  that  are  specific  to  the  intracellular  or
extracellular  compartments.  To  precisely  compare  the
myocilin isoforms in the cell lysate with those in the culture
media,  we  simultaneously  performed  all  experimental
procedures  including  the  sample  preparations  and  the
electrophoresis. In agreement with previous results, western
blot analysis following 2D-PAGE of cell lysates showed five
to six different myocilin isoforms ranging in pI from 5.0 to
5.4 and molecular weight from 55 to 57 kDa (Figure 3, upper
panel)  whereas  the  myocilin  in  concentrated  media  was
separated as multiple isoforms with pI ranging from 4.9 to 5.3
and molecular weight from 55 to 57 kDa (Figure 3, lower
panel). It is important to point out that a significant amount of
the myocilin isoforms with same mass and pI were found in
both the cell lysate and medium, although it is evident that
about half of the myocilin isoforms in the culture medium
were more acidic than those in the cell lysate. In addition to
the preceding data, these results consistently showed that there
were  no  myocilin  isoforms  found  only  in  the  ER  or
extracellular compartment.
Myocilin  is  not  completely  secreted:  The  absence  of  a
difference  between  the  intracellular  and  extracellular
myocilins led us to assume that the intracellular myocilin is a
protein that is embarking on the secretory pathway. To test
this possibility, we examined the trafficking of myocilin with
its  COOH-terminus  tagged  with  GFP  (myocilin-GFP).
Although most of the fusion protein was secreted as early as
1 h after chase and completed its secretion approximately 2 h
after chase, detectable amounts of the initial pulse remained
in the cells even 48 h after chase. In addition, there was no
intracellular  decay  observed  throughout  the  chase  period
(Figure 4A). Moreover, the treatment with the proteasomal
inhibitor, ALLN, had no effect on the decay (data not shown).
Taken  together,  these  results  suggest  that  myocilin  is
intrinsically very stable but an incompletely secreted protein.
To further explore the export of myocilin from HTM
cells, we repeated the above experiment but varied the level
of  myocilin  expression.  At  lower  expression  levels  as  in
Figure 4A, myocilin was mainly detected extracellularly. As
its  expression  was  increased,  however,  the  cellular
distribution of myocilin shifted to intracellular accumulation
and this gradually exceeded the extent of secretion from the
cells. Therefore, at a higher expression level, myocilin was
detected  preferentially  in  the  intracellular  compartment
(Figure 4B, upper panel). As a control, we monitored the
movement of stromelysin, a well known secretory protein,
which was secreted into the culture media regardless of its
expression levels (Figure 4B, lower panel).
Myocilin  is  retained  in  the  lumen  of  the  endoplasmic
reticulum: Because knowledge of the topology of a protein is
necessary for elucidating its identity, we studied the topology
of myocilin in the ER by the protease protection assay. We
prepared microsomal vesicles from the HTM cells expressing
myocilin-GFP  and  treated  the  membrane  vesicles  with
increasing concentrations of proteinase K in the presence or
absence of Triton X-100. Western blot analysis showed that
myocilin  was  completely  resistant  to  the  protease  in  the
absence of a detergent, but it was readily digested when the
membrane was disrupted with Triton X-100 (Figure 5, upper
panel), which is in accordance with a previous report [34]. We
also probed the same blot with a monoclonal antibody against
calnexin, a 90 kDa type I transmembrane protein primarily
located in the ER. In the absence of a detergent, the full-length
calnexin was all converted to a truncated form with its NH2-
terminal fragment exposed to the cytoplasmic face of the
membrane deleted while in the presence of a detergent, it was
completely  destroyed  (Figure  5,  lower  panel).  These  data
warrant  membrane  intactness  and  proteinase  K  activity,
thereby demonstrating that myocilin is a luminal ER protein.
Endoplasmic  reticulum  retention  of  myocilin  occurs  in  a
subset of cells: Previously, no myocilin staining was reported
even  with  DEX  exposure  in  many  TM  cells  and  most
Schlemm’s canal cells [35], ocular cells that along with TM
cells constitute the outflow pathway. Our results consistently
showed that the cultures transduced with Ad-myocilin-GFP
demonstrated green fluorescence corresponding to myocilin
expression  in  a  restricted  number  of  cells,  with  bright
fluorescence noted occasionally (Figure 6A). This expression
pattern  of  myocilin  is  easily  distinguished  from  that  of
myocilin mutants such as myocilin with the Y437H mutation
where  the  expression  is  discernable  in  nearly  all  cells,
although the signal is less weak. To understand the distinct
features of myocilin expression, we co-expressed wild-type
myocilin with myocilin mutant with the Y437H mutation and
thereby  selectively  inhibited  the  secretion  of  the  former
protein.  As  expected,  inhibition  of  wild-type  myocilin
secretion resulted in a dramatic increase in the number of cells
showing  wild-type  myocilin  expression.  Furthermore,  the
increase was proportional to the myocilin mutant expression
(Figure 6B). These results suggest that wild-type myocilin is
secreted  immediately  after  its  synthesis  from  most  cells,
making it hard to detect its expression. This explains why
myocilin expression is not detected in many HTM cells. To
better  understand  myocilin  expression,  HTM  cells  were
transduced  with  Ad-myocilin-GFP  that  was  covalently
labeled with CM-Dil. In general, the level of a transgene
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550expression in a cell is largely correlated with the degree with
which the viral particles carrying the gene enter the cell. The
correlation was observed only in about half of the transduced
cells (Figure 6C, right row). Approximately 40% of the cells
examined did not exhibit any myocilin expression as judged
by the brightness of the green fluorescence of the GFP when
compared to the extent of the viral uptake and as judged by
the brightness of the red fluorescence of the CM-Dil (Figure
6C,  middle  row).  The  remaining  10%  of  cells  showed
myocilin expression without any prominent signs of viral
infection (Figure 6C, left row). These results illustrate that the
degree of intracellular myocilin accumulation is not solely
determined by the extent of viral transduction. Perhaps it
might also be influenced to a certain extent by individual cell-
specific characteristics.
Intracellular accumulation of myocilin leads to endoplasmic
reticulum  stress  and  reduction  in  cell  proliferation:  One
explanation for the localization of myocilin to the ER is that
myocilin is retained inside cells because it is not correctly
folded or assembled in the ER. If this is true, myocilin may
lead to, as misfolded or unfolded proteins usually do, an ER
stress  response  such  as  unfolded  protein  response  (UPR),
Figure 4. Time-course analysis of the cellular trafficking of myocilin.
A: HTM cells transduced with Ad-myocilin-GFP at an MOI of 10
pfu were pulse labeled with [35S]methionine and chased for the times
indicated. After chase, the GFP fusion protein in the equal amount
of  cell  lysates  (~5  μg/well)  and  culture  media  were
immunoprecipitated  with  anti-GFP  antibody,  resolved  on  SDS–
PAGE, and then subjected to autoradiography. Each experiment was
performed three times with similar results. B: HTM cells transduced
with  Ad-myocilin-GFP  (upper  panel)  or  Ad-  stromelysin-GFP
(lower panel) at the indicated MOI were pulse labeled and chased for
4 h. The cells (C) and culture media (M) were separately harvested
and processed the same as in A. Each experiment was performed two
times with identical results. The bands resolved at approximately
68 kDa might be degraded products of stromelysin-GFP.
which may be followed by apoptotic cell death [36,37]. In
previous studies, we showed by western blot analysis and
WST-1  (4-[3-(4-Iodophenyl)-.  2-(4-nitrophenyl)-2H-5-
tetrazolio]-1,3-benzene disulfonate) cell proliferation assay
that wild-type myocilin did not trigger ER stress and was not
toxic to cells [16,17]. However, the biochemical assessments
may  have  been  inadequate  in  assaying  such  a  protein  as
myocilin since they demonstrate only average effects of all
the cells. To precisely evaluate the biological outcomes of
myocilin  expression,  cellular  responsiveness  to  myocilin
accumulation must be examined in individual cells.
In the present study, therefore, we reexamined using the
immunocytochemistry myocilin-induced ER stress response.
The results showed that the UPR could be activated with wild-
type myocilin expression as demonstrated by the upregulation
of GRP78 in the cells expressing myocilin-GFP but not in cells
without  myocilin-GFP  expression.  The  same  pattern  of
GRP78 induction was observed in the cultures expressing
myocilin-FLAG  as  well  as  the  myocilin  mutant  such  as
myocilin with the Y437H mutation (Figure 7A). By contrast,
the  induction  was  not  observed  in  cells  expressing  GFP-
tagged stromelysin, demonstrating that the observations were
not an artifact of the GFP tagging, protein overexpression, or
the viral infection.
We then assessed by fluorescence microscopy the effect
of myocilin expression on the proliferation of HTM cells. To
this  end,  we  transduced  HTM  cells  with  adenoviruses
expressing GFP, stromelysin-GFP, myocilin-GFP, or Y437H
Figure  5.  Determination  of  the  topology  of  myocilin  in  the
endoplasmic reticulum. The microsomal membrane was prepared
from HTM cells transduced with Ad-myocilin-GFP. The membrane
fractions were untreated (-) or treated with 1% Triton X-100 (+)
followed by the addition of increasing concentrations of protease K
(10 μg/ml in lane 1 and 2; 20 μg/ml in lane 3 and 4; 50 μg in lane 5
and 6; 100 μg lane 7 and 8). After digestion, the membrane was
probed with anti-myocilin antibody (upper panel), stripped, and re-
probed with anti-calnexin antibody (lower panel).
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551Figure  6.  Fluorescence  microscopic
analysis  of  myocilin  expression.  A:
HTM cells were transduced with Ad-
myocilin-GFP  (WT)  or  Ad-Y437H
myocilin-GFP (437) at an MOI of 10 pfu
and expressed for 48 h. After fixing and
staining  with  DAPI,  myocilin
expression (green) and DAPI staining
(blue)  were  merged.  Representative
images are shown of three independent
experiments. The graph is plotted values
showing  the  ratio  of  GFP-expressing
cells  to  nontransduced  cells.  Data
represents  means±standard  deviation
from  200  cells.  B:  HTM  cells  were
transduced with Ad-myocilin-FLAG at
an  MOI  of  10  pfu  followed  by
transduction  of  Ad-Y437H  myocilin-
GFP at an MOI of 0 pfu (left column), 5
pfu (middle column), and 10 pfu (right
column). Myocilin-FLAG was detected
with anti-FLAG antibody. Images of red
fluorescence  from  myocilin-FLAG
(upper row) or green fluorescence from
Y437H myocilin-GFP (lower row) were
merged with DAPI stains. Each column
represents  the  same  cells.
Representative  images  are  shown  of
three  independent  experiments.  The
graph is plotted values showing the ratio
of  red  fluorescence-positive  cells  to
nontransduced  cells.  Data  represents
means±standard  deviation  from  200
cells.  C:  HTM  cells  were  transduced
with red fluorescence (CM-Dil)-labeled
Ad-myocilin-GFP. Green (upper panel)
and  red  fluorescence  (lower  panel)
overlapped  with  nuclear  stains
correspond to myocilin expression and
cellular  uptake  of  viral  particles,
respectively.  Each  column  represents
the same cells. Representative images
are  shown  of  three  independent
experiments. Bar: 50 μm.
Molecular Vision 2009; 15:545-556 <http://www.molvis.org/molvis/v15/a55> © 2009 Molecular Vision
552myocilin-GFP and then calculated the ratio of cells expressing
each transgene versus the cells that did not express it 48 h or
96 h later. In the cells transduced with Ad-GFP, the ratio was
relatively constant. In the cells transduced with Ad-myocilin-
GFP, however, the ratio at the 96 h post-transduction was
approximately half of that at 48 h post-transduction. A similar
reduction in the ratio was observed with cells transduced with
Ad-Y437H myocilin-GFP (Figure 7B). These results suggest
that the replication of the cells expressing wild-type or mutant
myocilins was significantly inhibited compared to the cells
that were not transduced. These findings indicate that the
expression of not only mutant myocilin but also wild-type
myocilin appears to be toxic to cells.
DISCUSSION
In  this  study,  we  were  interested  in  understanding  the
mechanism by which myocilin is localized to both the ER and
extracellular compartments. The most common mechanism
by which products of a single gene are localized to more than
one cellular compartment is for each protein to be generated
with different topogenic information [30]. Hence, we first
tried to search for the presence of myocilin isoforms that are
topogenically different but failed to find such differences.
Essentially, intracellular myocilin does not differ from its
extracellular counterpart.
The present study confirmed the previous observations
that both intracellular and extracellular myocilins are resolved
on SDS–PAGE into glycosylated or non-glycosylated forms
and that these myocilins can be further separated on 2D-PAGE
into  multiple  spots  with  different  pIs  [22,23,33].  Strictly
speaking, however, the glycosylated and non-glycosylated
myocilins do not fulfill our criteria for myocilin isoforms with
respect  to  cellular  trafficking  because  both  are  equally
secreted. Similarly, the myocilin isoforms identified by 2D-
PAGE analysis also do not meet our criteria because most of
them are present intracellularly and extracellularly. Although
it was reported that myocilin undergoes post-transcriptional
modification giving rise to deleted forms [38], this finding was
not informative in that the event was examined only with
intracellular myocilin. Furthermore, this finding has not been
confirmed as yet by others. It was also reported that the Met-
Arg-Phe-Phe-Cys-Ala  sequence  (amino  acids  1–6)  was
obtained for the higher molecular mass of myocilin doublet
and the Arg-Thr-Ala-Gln-Leu sequence (amino acids 33–37)
was for the lower molecular mass of myocilin doublet [32].
However, these results are also not informative for the same
Figure  7.  Evaluation  of  the  potential
cytotoxicity of myocilin expression. A:
HTM cells were transduced with Ad-
myocilin-GFP  (WT),  Ad-myocilin-
FLAG (FLAG), Ad-Y437H myocilin-
GFP  (437),  or  Ad-stromelysin-GFP
(Str)  and  stained  for  GRP78.  FITC-
conjugated  anti-FLAG  antibody  and
DAPI was used to stain myocilin-FLAG
and nuclei, respectively. Each column
represents the same cells. The staining
patterns of each myocilin (green) and
GRP78 (red) merged with DAPI stains
are shown in the upper and lower rows,
respectively. Representative images are
shown  of  three  independent
experiments.  B:  HTM  cells  were
transduced  with  Ad-GFP  (GFP),  Ad-
stromelysin-GFP  (Str),  Ad-myocilin-
GFP  (WT),  or  Ad-Y437H  myocilin-
GFP (437) and cultured for 48 h (upper
row) or 96 h (lower row). After fixing
and  staining  with  DAPI,  the  green
fluorescence  of  GFP  or  GFP  fusion
proteins were merged with DAPI stains.
Representative  images  are  shown  of
three independent experiments. Bar: 50
μm. The graph is plotted values showing
the  ratio  of  GFP-expressing  cells  to
nontransduced  cells.  Data  represents
means±standard  deviation  from  200
cells.
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553reasons. Recently, Escribano et al. [26,34] have shown that
myocilin  undergoes  an  intracellular  endoproteolytic
processing, resulting in a 35 kDa fragment. In our experience,
however, the 35 kDa protein was occasionally observed even
when  myocilin  was  overexpressed  (data  not  shown).
Moreover, the fragment was detected in both the cells and
culture media, suggesting that it is not the ER specific or
extracellular compartment specific protein. Except for these
few reports, there is no published data regarding alternative
RNA splicing or different translational initiation, the most
common  mechanisms  that  enable  a  single  gene  to
differentially express multiple types of topogenic information
[30]. The early description that MYOC is composed of only
three different sized exons further suggests that alternative
RNA splicing seldom, if ever, occurs in this gene [32,39].
Taken together, our data and those from other investigators
strongly suggest that myocilin isoforms that are different in
both their primary structure and topogenic information do not
exist.
In this study, we demonstrated that myocilin was not
completely secreted but accumulated in the lumen of the ER
over time. Many luminal ER proteins have at their COOH-
terminus a tetrapeptide Lys-Asp-Glu-Leu (KDEL) sequence
and display posttranslational modifications that are performed
by enzymes in the Golgi apparatus, demonstrating that they
escape the ER at least once during their lifetime [40,41].
However, myocilin does not have the KDEL sequence. In
addition,  myocilin  did  not  respond  to  Endo  D  digestion,
suggesting that it never leaves the ER. Furthermore, myocilin
was  not  evenly  expressed  in  cells  transduced  with  the
adenovirus expressing myocilin. Therefore, these results do
not indicate that myocilin is a cytosolic protein destined for
localization in the ER.
Although most MYOC mutations that are associated with
glaucoma  are  missense  substitutions  [7-9],  myocilin  with
these mutations usually manifest phenotypes such as Triton
insolubility [42], formation of intracellular aggregates [14,
16-18], and blockage of secretion [14,15,17]. This suggests
that myocilin is prone to misfolding. It has been reported that
a very high proportion (30%) of all newly synthesized proteins
are  defective,  but  they  are  apparently  degraded  by
proteasomes shortly after their synthesis [43]. The present
study showed that such was not the case with myocilin in that
it was relatively resistant to proteasomal degradation. The
accumulation of such proteins as myocilin that are misfolded
and not degraded may be potentially detrimental to cells. We
observed that the cells expressing myocilin always expressed
GRP78, the master regulator of UPR as well as ER stress
[36]. This observation suggests that intracellular myocilin is
a protein similar to its mutant forms where it is localized to
the ER by default and at this location is potentially cytotoxic.
Recent  studies  have  investigated  transgenic  mice
homozygous for MYOC and estimated the steady-state level
of myocilin in the AH of the mice, demonstrating that mice
overexpressing  the  wild-type  myocilin  did  not  develop
elevated IOP or glaucoma [44,45]. These results suggest that
increasing the amounts of myocilin alone is not sufficient to
cause glaucoma. However, these findings do not mean that
intracellular myocilin itself is not harmful to cells. Therefore,
one  might  speculate  that  various  published  biological
outcomes associated with myocilin [46,47] may be attributed
to the potential cytotoxicity of myocilin expression.
In  summary,  the  present  study  investigated  whether
intracellular wild-type myocilin is a true ER resident protein
and showed that myocilin is likely a mistargeted protein rather
an  ER  protein.  Therefore,  the  role  myocilin  plays  in  the
development of POAG may be greater than initially predicted.
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